OVERVIEW

Our most advanced program, MDNA55, specifically targets the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna’s lead IL4-EC, MDNA55 is currently enrolling patients in a Phase 2b clinical trial for rGBM at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA.

Unlike most other cancer therapies, Medicenna’s IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment (TME), offering a unique treatment paradigm for a large majority of cancer patients.

Our approach to treat brain and other aggressive cancers received strong validation by a recent award of a $14.1M non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The treatment plan for the MDNA55 clinical trial includes our IL4R targeted drug MDNA55, precision image-guided convection enhanced delivery (CED) and real-time monitoring of drug distribution to ensure optimal delivery of the drug.

Treatment involves direct one-time intra-tumoral infusion of MDNA55 using CED. Image guided CED provides intra-tumoral delivery with sub-millimeter precision and real-time monitoring ensures uniform distribution of MDNA55 into the brain tumor and its infiltrative edges. We believe that this personalized approach by-passes the blood brain barrier (BBB), avoids potential systemic side effects and has the potential to reduce the risk of tumor recurrence – problems that have continued to plague this difficult to treat disease.

In addition to brain cancers, the IL4R is a marker for highly aggressive forms of solid and blood tumors affecting more than a million new cancer patients every year. The IL4/IL4R bias is known to play a central role in the establishment of a robust immunosuppressive tumor micro-environment (TME), is expressed by cancer stem cells and is generally associated with poor survival outcomes. MDNA55 and Medicenna’s next generation fully human IL4-EC platform (MDNA57) have the potential to mature into an important class of treatments addressing large unmet needs in oncology.

Top